Cytek Biosciences (NASDAQ:CTKB) Issues Earnings Results

Key Points

• Cytek Biosciences reported Q1 revenue of $44.1 million, up 6% year over year and roughly in line with expectations, with U.S. sales rebounding strongly to $24.4 million, up 32%.
• Profitability worsened as the company posted a GAAP net loss of $18.9 million and an adjusted EBITDA loss of $9.1 million, driven by higher operating costs and increased G&A spending tied to patent litigation and consulting.
• Management kept full-year guidance unchanged at $205 million to $212 million and noted a cash balance of $262.2 million, while recurring revenue and the installed base continued to grow.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) released its earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.07), FiscalAI reports. The firm had revenue of $44.14 million during the quarter, compared to analyst estimates of $44.23 million. Cytek Biosciences had a negative return on equity of 9.81% and a negative net margin of 36.25%.

Here are the key takeaways from Cytek Biosciences' conference call:

• Q1 revenue was $44.1M (up 6% YoY), led by a strong U.S. rebound with U.S. revenue of $24.4M (up 32%), indicating recovering instrument demand.
• Recurring revenue (reagents + service) reached $18.4M and now represents 35% of trailing 12‑month revenue (19% YoY growth); installed base grew by 125 units to 3,789 and the Aurora Evo is driving product traction.
• Profitability worsened—GAAP net loss widened to $18.9M (from $11.4M) and adjusted EBITDA loss was $9.1M, driven by a 13% rise in operating expenses and a $5.6M increase in G&A largely from patent litigation and consulting.
• Management reaffirmed full‑year guidance of $205M–$212M (2%–5% growth), holds $262.2M in cash and expects to deliver positive adjusted EBITDA for full year 2026.

Cytek Biosciences Stock Performance

Shares of NASDAQ CTKB traded down $0.31 during trading on Friday, hitting $4.61. The company had a trading volume of 1,361,764 shares, compared to its average volume of 600,220. The company has a market cap of $595.34 million, a P/E ratio of -8.09 and a beta of 1.22. Cytek Biosciences has a 52 week low of $2.37 and a 52 week high of $6.18. The business's 50-day moving average is $4.48 and its 200 day moving average is $4.75.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Federated Hermes Inc. raised its stake in Cytek Biosciences by 150.9% during the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock valued at $25,000 after purchasing an additional 4,343 shares during the period. Captrust Financial Advisors acquired a new stake in Cytek Biosciences during the 2nd quarter valued at $43,000. CIBC Bancorp USA Inc. acquired a new stake in Cytek Biosciences during the 3rd quarter valued at $43,000. Tower Research Capital LLC TRC raised its stake in Cytek Biosciences by 338.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 19,760 shares of the company's stock valued at $67,000 after purchasing an additional 15,250 shares during the period. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in Cytek Biosciences during the 3rd quarter valued at $75,000. Institutional investors own 69.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Cytek Biosciences in a research report on Friday, March 27th. TD Cowen reaffirmed a "buy" rating on shares of Cytek Biosciences in a report on Thursday, January 8th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $5.38.

About Cytek Biosciences

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company's core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.